The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $58.86

Today's change+0.34 +0.58%
Updated November 26 4:02 PM EST. Delayed by at least 15 minutes.
 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $58.86

Today's change+0.34 +0.58%
Updated November 26 4:02 PM EST. Delayed by at least 15 minutes.

Bristol-Myers Squibb Co up (U.S.)$0.34

Bristol-Myers Squibb Co closed up Wednesday by (U.S.)$0.34 or 0.58% to (U.S.)$58.86. Over the last five days, shares are unchanged, but are currently 1.08% below its 52-week high. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $58.69
  • Previous close(U.S.) $58.52
  • High(U.S.) $58.90
  • Low(U.S.) $58.36
  • Bid / Ask-- / --
  • YTD % change+10.74%
  • Volume3,746,655
  • Average volume (10-day)5,444,458
  • Average volume (1-month)7,673,177
  • Average volume (3-month)6,506,345
  • 52-week range(U.S.) $46.30 to (U.S.) $59.50
  • Beta0.33
  • Trailing P/E36.15×
  • P/E 1 year forward32.67×
  • Forward PEG3.01×
  • Indicated annual dividend(U.S.) $1.44
  • Dividend yield2.45%
  • Trailing EPS(U.S.) $1.63
Updated November 26 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+17.04%

Based on its net profit margin of 17.04%, Bristol-Myers Squibb Co is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.74%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue3,9213,8893,8114,441
Total other revenue--------
Total revenue3,9213,8893,8114,441
Gross profit2,9502,9372,8883,168
Total cost of revenue9719529231,273
Total operating expense3,2103,4493,0903,586
Selling / general / administrative1,2001,1381,1201,322
Research & development918958898957
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)19253820766
Other operating expenses, total-71-137-58-32
Operating income711440721855
Interest income (expense), net non-operating-50-46-54-53
Gain (loss) on sale of assets315-72591
Other--------
Income before tax1,008448985869
Income after tax732334936735
Income tax, total27611449134
Net income721333937726
Total adjustments to net income------0
Net income before extra. items721333937726
Minority interest-11-11-9
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items721333937726
Inc. avail. to common incl. extra. items721333937726
Diluted net income721333937726
Dilution adjustment--------
Diluted weighted average shares1,6701,6691,6661,671
Diluted EPS excluding extraordinary itemsvalue per share0.430.200.560.43
Dividends per sharevalue per share0.360.360.360.35
Diluted normalized EPSvalue per share0.350.580.600.36